
Making the Medicines of Tomorrow

Lonza
Integrated Biologics



Early expression decisions. Lasting impact.

The future of your biologic candidate starts with the platform you choose today.

Early expression platform decisions can have lasting consequences. Using a proven expression system from the outset helps de-risk development, generate representative data early, support regulatory readiness and drive long-term manufacturing success, while keeping pace with the evolving demands of today's diverse biologics.

Proven performance. Continual innovation.

A proven platform should never stand still. Trusted across more than 100 commercial products, the GS Gene Expression System® platform continues to evolve alongside the needs of modern biologics. GS Ori-Go® vectors are the latest advancement, delivering a faster route to high-performing stable cell lines.[1]

- DNA-to-IND in as little as 6 months.[2]
- High titers with no compromise to product quality or expression stability.
- Streamlined workflows that accelerate progression to tox and IND-enabling studies.[1]




Figure 1
Fed-batch expression of a one-armed antibody (triple gene vector)

[1] Compared to the GS Gene Expression System® platform without GS Ori-Go® vectors.
[2] From DNA transfection to delivery of IND-enabling CMC modules. Typical timelines. Subject to terms and conditions.

Making the Medicines of Tomorrow


Lonza
Integrated Biologics

GS Gene Expression System®

Up to 11g/L titers	100+ commercial products	40+ years' expertise
for a range of molecules	with the GS® platform	in bioproduction at Lonza

One platform. Fewer surprises.

Use the same proven expression technologies from discovery through commercial manufacture. Evaluating candidates in a proven, commercially relevant CHO expression system helps generate more representative data early, enabling informed decisions before development pathways become more complex, costly and difficult to change.



Flexible access. Same technology.

Access GS® technologies directly in your own lab through a research license, or leverage Lonza's services at any stage of development, from early protein expression and developability assessments through to cell line development and manufacturing. Whichever path you choose, you'll be supported by experts with decades of collective experience. Because it's all built on the same GS Gene Expression System® platform, moving between in-house activities and Lonza's services is straightforward, with no need to change systems or start again.

Lonza in Your Lab®
Research license

- Covers all preclinical work[3]
- Portable[3]
- Flexible licenses

GS®
Same technology at every stage

Lonza Services
At any stage

- Early protein expression and developability
- Cell line development
- GMP manufacturing

[3] Subject to the terms and conditions of the license agreement.

Visit the website.
Click or scan the QR Code.

Contact us
Email: **licensing@lonza.com**

The information contained herein is believed to be correct and corresponds to the latest state of scientific and technical knowledge. However, no warranty is made, either expressed or implied, regarding its accuracy or the results to be obtained from the use of such information. Lonza disclaims any liability for the use of this information and the use of the information contained herein is at your own risk. Any user must make his own determination and satisfy himself that the information provided is (i) suitable for intended process or purpose, (ii) in compliance with environmental, health and safety regulations, and (iii) will not infringe any third party's intellectual property rights. All trademarks belong to Lonza and are registered in CH, US and/or EU, or used in common law or belong to their respective third-party owners and are only being used for informational purposes.

©2026 Lonza. All rights reserved.

Lonza Edition No. v 1.0. 11-2026